These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23541423)

  • 41. Tolerability of NXY-059 at higher target concentrations in patients with acute stroke.
    Lees KR; Barer D; Ford GA; Hacke W; Kostulas V; Sharma AK; Odergren T;
    Stroke; 2003 Feb; 34(2):482-7. PubMed ID: 12574564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Protective effects of cilostazol against transient focal cerebral ischemia and hemorrhagic transformation].
    Ishiguro M; Hara H
    Yakugaku Zasshi; 2011 Apr; 131(4):513-21. PubMed ID: 21467790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preventive Effect of Cilostazol on Pneumonia in Patients with Acute Cerebral Infarction.
    Nakamura Y; Nakajima H; Kimura F; Unoda K; Arawaka S
    J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2354-2359. PubMed ID: 29759939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.
    Lee JH; Park SY; Shin HK; Kim CD; Lee WS; Hong KW
    CNS Neurosci Ther; 2008; 14(2):143-52. PubMed ID: 18482026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage.
    Yu KH; Hong KS; Oh MS; Lee J; Lee JS; Kwon SU;
    J Stroke Cerebrovasc Dis; 2016 Aug; 25(8):2061-6. PubMed ID: 27263034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Changes in Mean Platelet Volume after Using of Antiplatelet Drugs in Acute Ischemic Stroke: A Randomized Controlled Trial.
    Haungsaithong R; Udommongkol C; Nidhinandana S; Chairungsaris P; Chinvarun Y; Suwantamee J; Sithinamsuwan P
    J Med Assoc Thai; 2015 Sep; 98(9):852-7. PubMed ID: 26591394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
    Ohtake T; Sato M; Nakazawa R; Kondoh M; Miyaji T; Moriya H; Hidaka S; Kobayashi S
    Ther Apher Dial; 2014 Feb; 18(1):1-8. PubMed ID: 24499078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Administration of cilostazol, an antiplatelet, to patients with acute-stage cerebral infarction and its effects on plasma substance P level and latent time of swallowing reflex.
    Abe A; Nishiyama Y; Hagiwara H; Okubo S; Ueda M; Katsura K; Katayama Y
    J Nippon Med Sch; 2013; 80(1):50-6. PubMed ID: 23470806
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients.
    Matsumoto S; Shimodozono M; Miyata R; Kawahira K
    Int J Neurosci; 2011 May; 121(5):271-8. PubMed ID: 21348793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke.
    Kwon HM; Lee YS; Bae HJ; Kang DW
    Stroke; 2014 Mar; 45(3):871-3. PubMed ID: 24448992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.
    Shiohira S; Yoshida T; Sugiura H; Yoshida S; Mitobe M; Shimada K; Ohba T; Tsuchiya K; Kabaya T; Nitta K
    Clin Exp Nephrol; 2011 Dec; 15(6):893-9. PubMed ID: 21773691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of post-stroke disuse muscle atrophy with a free radical scavenger.
    Naritomi H; Moriwaki H
    Front Neurol Neurosci; 2013; 32():139-47. PubMed ID: 23859973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cilostazol Use Is Associated with Reduced Risk of Dementia: A Nationwide Cohort Study.
    Tai SY; Chien CY; Chang YH; Yang YH
    Neurotherapeutics; 2017 Jul; 14(3):784-791. PubMed ID: 28194663
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis.
    Jung SJ; Shim SR; Kim BJ; Jung JM
    J Neurol Sci; 2022 Nov; 442():120457. PubMed ID: 36272270
    [No Abstract]   [Full Text] [Related]  

  • 55. Review of Toyoda K,
    Lo BWY; Miyawaki S; Fukuda H; Koyanagi M
    Surg Neurol Int; 2020; 11():53. PubMed ID: 32363048
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis.
    Taguchi A; Takata Y; Ihara M; Kasahara Y; Tsuji M; Nishino M; Stern D; Okada M
    Psychogeriatrics; 2013 Sep; 13(3):164-9. PubMed ID: 25707423
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing Cerebralcare Granule and aspirin for neurological dysfunction in acute stroke in real-life practice.
    Zhao L; Liao L; Hu F
    Psychogeriatrics; 2017 Jan; 17(1):3-8. PubMed ID: 26757022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Efficacy and safety of the combined therapy with citicholine and actovegin in the acute period of ischemic stroke].
    Shamalov NA; Stakhovskaia LV; Shetova IM; Efremova NM; Anisimov KV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(9 Pt 2):13-7. PubMed ID: 21462435
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cilostazol reduces PAC-1 expression on platelets in ischemic stroke.
    Lee SY; Kang MJ; Cha JK
    J Clin Neurol; 2008 Dec; 4(4):148-52. PubMed ID: 19513289
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cilostazol for treatment of cerebral infarction.
    Noma K; Higashi Y
    Expert Opin Pharmacother; 2018 Oct; 19(15):1719-1726. PubMed ID: 30212227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.